Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, the Netherlands was one of the first countries to implement R-biosimilars, given lower costs compared with rituximab originator (R-originator). Th...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2021-08, Vol.5 (15), p.2958-2964
Hauptverfasser:	Brink, Mirian, Kahle, Xaver U., Vermaat, Joost S.P., Zijlstra, Josee M., Chamuleau, Martine, Kersten, Marie José, Durmaz, Müjde, Plattel, Wouter J., Lugtenburg, Pieternella J., Stevens, Wendy, Mous, Rogier, de Vries, Elisabeth G.E., van der Poel, Marjolein W.M., Panday, Prashant V. Nannan, Huls, Gerwin, van Meerten, Tom, Nijland, Marcel
Format:	Artikel
Sprache:	eng
Schlagworte:	Lymphoid Neoplasia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!